Fiduciary Financial Group’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$616K Buy
3,929
+37
+1% +$5.55K 0.07% 163
2026
Q1
$595K Buy
3,892
+215
+6% +$33K 0.08% 155
2025
Q4
$507K Sell
3,677
-172
-4% -$22.5K 0.07% 160
2025
Q3
$494K Buy
3,849
+207
+6% +$25.3K 0.08% 151
2025
Q2
$448K Buy
3,642
+47
+1% +$5.3K 0.08% 148
2025
Q1
$372K Sell
3,595
-384
-10% -$40.9K 0.08% 149
2024
Q4
$394K Buy
3,979
+81
+2% +$8.64K 0.09% 143
2024
Q3
$443K Buy
3,898
+118
+3% +$13.4K 0.1% 121
2024
Q2
$418K Buy
+3,780
New +$379K 0.1% 122

Other funds holding NVS

Fiduciary Financial Group's NVS Position: Q2 2026 in Review

Fiduciary Financial Group increased its Novartis (NVS) stake by 0.95% in Q2 2026, buying an estimated $5.55K and bringing the position to 3,929 shares worth $616K. The position accounts for 0.07% of the portfolio, ranked #163.

Fiduciary Financial Group first reported a position in NVS in Q2 2024 and has held it in 9 quarters since. 727 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Fiduciary Financial Group held 3,929 shares of Novartis worth $616K as of Q2 2026.
  • Fiduciary Financial Group bought 37 Novartis shares in Q2 2026, an estimated $5.55K.
  • Novartis made up 0.07% of Fiduciary Financial Group's portfolio in Q2 2026, its #163 holding.
  • Fiduciary Financial Group first reported a position in Novartis in Q2 2024 and has held it in 9 quarters since.
  • 727 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Fiduciary Financial Group's 13F filing for Q2 2026, filed 10 Jul 2026.